Figure 4. Bevacizumab-induced Inhibition of Differentiation of Retinoblastoma Cells through Blockade of ERK 1/2 Activation.

SNUOT-Rb1 cells were treated with 0.1% BSA or 1 mg/ml bevacizumab. ERK 1/2, phospho-ERK 1/2, Akt, and phospho-Akt were detected by Western blot analysis. β-actin was served as a loading control. Each figure is representative ones from three independent experiments. Quantitative analysis was performed by measuring protein expression relative to the controls. Each value represents means ± SE from three independent experiments (*P<0.05, **P>0.05). BSA, bovine serum albumin.